Russian version English version
About the Journal
Editorial Board
Instructions for Authors
Information for Readers and Authors
Current Issue
Archive
Contact Us
Search

Send manuscript
 


Volume 18   Issue 1   Year 2023
Borodulina A.D.1,2, Kutumova E.O.1,2,3,4, Lifshits G.I.5, Kolpakov F.A.2,3,4

Mathematical Modeling of Antihypertensive Therapy with Azilsartan Medoxomil on the Example of Clinical Data of a Real Patient

Mathematical Biology & Bioinformatics. 2023;18(1):228-250.

doi: 10.17537/2023.18.228.

References

  1. Chazova I.E., Zhernakova Y.V. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertension. 2019;16(1):6-31. doi: 10.26442/2075082X.2019.1.190179
  2. Boytsov S.A., Balanova Yu.A., Shalnova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Konradi A.O. et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from eccd. Cardiovascular Therapy and Prevention. 2014;13(4) (in Russ.). doi: 10.15829/1728-8800-2014-4-4-14
  3. Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S., White I.R., Caulfield M.J., Deanfield J.E., Smeeth L., et al. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet (London, England). 2014;383(9932):1899-1911. doi: 10.1016/S0140-6736(14)60685-1
  4. Britov A.N. Prevention of arterial hypertension at the population level: Opportunities and current challenges. Russian Medical Journal. 1997;5(9) (in Russ.).
  5. Oparil S., Acelajado M.C., Bakris G.L., Berlowitz D.R., Cífkova R., Dominiczak A.F., Grassi G., Jordan J., Poulter N.R., Rodgers A., et al. Hypertension. Nature Reviews Disease Primers. 2018;4. Article No. 18014. doi: 10.1038/nrdp.2018.14
  6. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A., de Simone G., Dominiczak A. et al. ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339
  7. Karaaslan F., Denizhan Y., Kayserilioglu A., Gulcur H.O. Long-term mathematical model involving renal sympathetic nerve activity, arterial pressure, and sodium excretion. Annals of Biomedical Engineering. 2005;33(11):1607-1630. doi: 10.1007/s10439-005-5976-4
  8. Hallow K.M., Lo A., Beh J., Rodrigo M., Ermakov S., Friedman S., de Leon H., Sarkar A., Xiong Y., Sarangapani R., et al. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: Extending the Guyton model. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2014;306(9):R647-R662. doi: 10.1152/ajpregu.00039.2013
  9. Hallow K.M., Gebremichael Y. A quantitative systems physiology model of renal function and blood pressure regulation: Model description. CPT: Pharmacometrics and Systems Pharmacology. 2017;6(6):383-392. doi: 10.1002/psp4.12178
  10. Proshin A.P., Solodyannikov Y.V. Mathematical modeling of blood circulation system and its practical application. Autom Remote Control. 2006;67:329-341. doi: 10.1134/S000511790602010X
  11. Kutumova E., Kiselev I., Sharipov R., Lifshits G., Kolpakov F. Thoroughly Calibrated Modular Agent-Based Model of the Human Cardiovascular and Renal Systems for Blood Pressure Regulation in Health and Disease. Frontiers in Physiology. 2021;12. doi: 10.3389/fphys.2021.746300
  12. Kutumova E., Kiselev I., Sharipov R., Lifshits G., Kolpakov F. Mathematical modeling of antihypertensive therapy. Front Physiol. 2022;13. doi: 10.3389/fphys.2022.1070115
  13. Chazova I.Y., Zhernakova Y.V., Blinova N.V., Rogoza A.N. The new angiotensin II receptor blocker Edarbi as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders. Systemic Hypertension. 2017;14(3). Article No. 3. doi: 10.26442/SG29582
  14. Bonner G., Bakris G., Sica D., Weber M.A., White W.B., Perez A., Cao C., Handley A., Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. PubMed. 2013. doi: 10.1038/jhh.2013.6
  15. Martynyuk T.V., Chazova I.E. Advantages azilsartan medoxomil in patients with arterial hypertension: how to make a choice and to optimize antihypertensive therapy? Systemic Hypertension . 2017;14(2):45-50 (in Russ.). doi: 10.26442/SG29188
  16. Nedogoda S.V., Chumachek E.V., Tsoma V.V., Salasyuk A.S., Smirnova V.O., Popova E.A. Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs. Russian Journal of Cardiology. 2019(1):70-79. doi: 10.15829/1560-4071-2019-1-70-79
  17. Kolpakov F., Akberdin I., Kashapov T., Kiselev L., Kolmykov S., Kondrakhin Y., Kutumova E., Mandrik N., Pintus S., Ryabova A., et al. BioUML: An integrated environment for systems biology and collaborative analysis of biomedical data. Nucleic Acids Research. 2019;47(W1):W225-W233. doi: 10.1093/nar/gkz440
  18. Kolpakov F., Akberdin I., Kiselev I., Kolmykov S., Kondrakhin Y., Kulyashov M., Kutumova E., Pintu, S., Ryabova A., Sharipov R., et al. BioUML-towards a universal research platform. Nucleic Acids Research. 2022;50(W1):W124-W131. doi: 10.1093/nar/gkac286
  19. Stephanou A., Volpert V. Hybrid Modelling in Biology: A Classification Review. Mathematical Modelling of Natural Phenomena. 2016;11(1). Article No. 1. doi: 10.1051/mmnp/201611103
  20. Hindmarsh A. SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers. ACM Transactions on Mathematical Software. 2005;31(3). doi: 10.1145/1089014.1089020
  21. Soheilypour M., Mofrad M. Agent‐Based Modeling in Molecular Systems Biology. BioEssays: news and reviews in molecular, cellular and developmental biology. 2018. doi: 10.1002/bies.201800020
  22. Alwi I. Diagnosis and management of cardiogenic pulmonary edema. Acta Medica Indonesiana. 2010;42(3):176-184.
  23. Grigoryev E.V., Bautin A.E., Kirov M.Yu., Shukevich D.L., Kornelyuk R.A. Cardiogenic shock associated with acute coronary syndrome: The current state of the problem of diagnostics and intensive care. Article. Annals of Critical Care. 2020;2:73-85. doi: 10.21320/1818-474X-2020-2-73-85
  24. Nadler S., Hidalgo J., Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962. doi: 10.5555/uri:pii:0039606062901666
  25. Rakugi H., Enya K., Sugiura K., Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: A randomized, double-blind clinical study. Hypertension Research. 2012;35(5). Article No. 5. doi: 10.1038/hr.2012.8
  26. White W., Weber M., Sica D. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. Hypertension. 2011;57:413-420 doi: 10.1161/HYPERTENSIONAHA.110.163402
  27. Kario K., Hoshide S. Age-Related Difference in the Sleep Pressure-Lowering Effect Between an Angiotensin II Receptor Blocker and a Calcium Channel Blocker in Asian Hypertensives. Hypertension. 2015;65:729-735 doi: 10.1161/HYPERTENSIONAHA.114.04935
  28. Schmieder R.E., Potthoff S.A., Bramlage P., Baumgart P., Mahfoud F., Buhck H., Ouarrak T., Ehmen M., Senges J., Gitt A.K. Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin‐Converting Enzyme Inhibitors: The Prospective EARLY Registry. The Journal of Clinical Hypertension. 2015;17(12):947-953. doi: 10.1111/jch.12603
  29. Bakris G. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. The Journal of Clinical Hypertension. 2011;13(2):81-88. doi: 10.1111/j.1751-7176.2010.00425.x
  30. Weber M.A., White W.B., Sica D., Bakris G.L., Cao C., Roberts A., Kupfer S. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Pressure Monitoring. 2014;19(2):90-97. doi: 10.1097/MBP.0000000000000027
  31. Bakris G. Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. The American Journal of Medicine. 2012;125(12). doi: 10.1016/j.amjmed.2012.05.023
  32. Hiromi Rakugia, Kohei Shimizub, Yuya Nishiyamab, Yuhei Sanob, Yuusuke Umedab. A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. Blood Pressure. 2018;27(3):125-133. doi: 10.1080/08037051.2017.1412797
  33. Angeloni E. Azilsartan medoxomil in the management of hypertension: An evidence-based review of its place in therapy. Core Evidence. 2016;11:1-10. doi: 10.2147/CE.S81776
  34. Dargad R., Parekh J., Kukrety S. Azilsartan: Novel Angiotensin Receptor Blocker. The Journal of the Association of Physicians of India. 2016;64:96-98. https://pubmed.ncbi.nlm.nih.gov/27731574/ (accessed 23 February 2023).
  35. Jones J.D., Jackson S.H., Agboton C., Martin T.S. Azilsartan Medoxomil (Edarbi). Pharmacy and Therapeutics. 2011;36(10):634-640. https://pubmed.ncbi.nlm.nih.gov/22346296/ (accessed 23 February 2023).
  36. Makani H., Bangalore S., Supariwala A., Romero J., Argulian E., Messerli F.H. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis. European Heart Journal. 2014;35(26):1732-1742. doi: 10.1093/eurheartj/eht333
  37. Zaiken K., Cheng J.W.M. Azilsartan Medoxomil: A New Angiotensin Receptor Blocker. Clinical Therapeutics. 2011;33(11):1577-1589. doi: 10.1016/j.clinthera.2011.10.007
Table of Contents
Original Article
Math. Biol. Bioinf.
2023;18(1):228-250
doi: 10.17537/2023.18.228
published in Russian

Abstract (rus.)
Abstract (eng.)
Full text (rus., pdf)
References

 
  Copyright IMPB RAS © 2005-2024